How Safe Is that Flight? Auditors Question Airport Security
A government spat between Congress and the Transportation Safety Administration yesterday raised a question: Is the TSA trying to stonewall a congressional committee looking into reports suggesting the agency may be failing in its $7 billion-a-year mission to safeguard airports and air travel from terrorist threats?
At the start of Wednesday’s TSA: Are Airports Safe? hearing, House Oversight Committee Chairman Jason Chaffetz (R-UT ) immediately pointed out a glaring absence from the witness panel—the TSA.
Related: Poor Maintenance Could Make that Airport Scanner a Dud
Chaffetz said the committee had invited TSA acting administrator Melvin Carraway, but the agency offered a lower-level official in his place.
“The Department of Homeland Security objected to [Carraway’s] presence on the panel because they felt it was demeaning to have the acting director sit on the same panel as a private sector witness,” he said, referring to Raffi Fron, president of New Age Security Solutions, a company that provides security systems such as video surveillance.
The hearing was prompted by two separate but equally scathing watchdog reports that question the TSA’s ability to effectively screen passengers.
“Our audits have repeatedly found that human error— often a simple failure to follow protocol—poses significant vulnerabilities,” DHS’s IG John Roth said—adding that despite offering hundreds of recommendations the TSA has failed to assure that its mission is succeeding.
Related: Report Says TSA Wasted $1 Billion on Screening Program
DHS stood by its decision not to send its acting administrator. An agency official told The Fiscal Times that the department only participates in congressional hearing panels with other government agencies—not with private-sector witnesses in order to avoid conflicts of interest.
A spokesperson for the committee said that “witness invitations are not transferable” and that the “DHS does not dictate how we run our hearings.”
This isn’t the only roadblock the Oversight Committee has run into with the TSA. During the hearing, Chairman Chaffetz showed off a heavily redacted document he had requested from the agency—saying even members of Congress had “exceptional” difficulties getting information from them.
The committee spokesperson said House Oversight is currently looking into other ways the TSA has frustrated congressional inquiries—and what kinds of action can be taken.
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.